IL195493A0 - Combination preparations comprising bifeprunox and l-dopa - Google Patents

Combination preparations comprising bifeprunox and l-dopa

Info

Publication number
IL195493A0
IL195493A0 IL195493A IL19549308A IL195493A0 IL 195493 A0 IL195493 A0 IL 195493A0 IL 195493 A IL195493 A IL 195493A IL 19549308 A IL19549308 A IL 19549308A IL 195493 A0 IL195493 A0 IL 195493A0
Authority
IL
Israel
Prior art keywords
bifeprunox
dopa
combination preparations
preparations
combination
Prior art date
Application number
IL195493A
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of IL195493A0 publication Critical patent/IL195493A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL195493A 2006-06-16 2008-11-25 Combination preparations comprising bifeprunox and l-dopa IL195493A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81405206P 2006-06-16 2006-06-16
EP06115587 2006-06-16
PCT/EP2007/055956 WO2007144422A2 (en) 2006-06-16 2007-06-15 Combination preparations comprising bifeprunox and l-dopa

Publications (1)

Publication Number Publication Date
IL195493A0 true IL195493A0 (en) 2009-09-01

Family

ID=38691894

Family Applications (1)

Application Number Title Priority Date Filing Date
IL195493A IL195493A0 (en) 2006-06-16 2008-11-25 Combination preparations comprising bifeprunox and l-dopa

Country Status (9)

Country Link
EP (1) EP2037964A2 (en)
JP (1) JP2009539942A (en)
KR (1) KR20090033871A (en)
AU (1) AU2007259256A1 (en)
CA (1) CA2654557A1 (en)
EA (1) EA014576B1 (en)
IL (1) IL195493A0 (en)
NO (1) NO20090165L (en)
WO (1) WO2007144422A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102131503A (en) * 2008-06-30 2011-07-20 诺瓦提斯公司 Combination products comprising mGluR modulator for treating parkinson's disease
ITMI20100260A1 (en) * 2010-02-19 2011-08-20 Giulio Scigliano PHARMACEUTICAL COMPOSITION CONTAINING A DRUG TO REDUCE THE SIDE EFFECTS OF ANTIPSYCHOTIC DRUGS
PL2627328T3 (en) * 2010-10-15 2017-03-31 Contera Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders
PL2838517T3 (en) 2012-04-18 2018-03-30 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders
CN111454290B (en) * 2014-10-21 2022-12-23 艾伯维公司 Carbidopa and levodopa prodrugs and their use for treating parkinson's disease
CN109689036A (en) 2016-07-11 2019-04-26 康特拉医药公司 For treating morning akinetic pulse delivery system

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045362A1 (en) * 2003-08-18 2005-10-26 Solvay Pharm Bv STABLE CRYSTALLINE FORM OF BIFEPRUNOX MESILATE (MONOMETANSULFONATE 7- [4 - ([1,1- BIFENIL] -3- ILMETIL) -1- PIPERAZINIL] - 2- (3H) -BENZOXAZOLONA

Also Published As

Publication number Publication date
KR20090033871A (en) 2009-04-06
CA2654557A1 (en) 2007-12-21
AU2007259256A1 (en) 2007-12-21
EP2037964A2 (en) 2009-03-25
WO2007144422A2 (en) 2007-12-21
EA014576B1 (en) 2010-12-30
WO2007144422A3 (en) 2008-03-13
EA200970022A1 (en) 2009-06-30
JP2009539942A (en) 2009-11-19
NO20090165L (en) 2009-01-12

Similar Documents

Publication Publication Date Title
IL194688A0 (en) Rapid acting and long acting insulin combination formulations
HK1138188A1 (en) Solid preparation comprising alogliptin and pioglitazone
ZA200810790B (en) Stable laquinimod preparations
EP2039347A4 (en) Cosmetic hair preparation
EP1951762A4 (en) Compositions and methods for improved skin care
PL2059223T3 (en) Skin care composition
HK1244819A1 (en) Foxm1 peptide and medicinal agent comprising the same
IL194751A0 (en) Drugs and uses
EP1879449A4 (en) Compositions and methods for skin care
GB0516069D0 (en) Pharmaceutical and use thereof
GB2443336B (en) Spiruchostatin analogues and their medicinal use
IL193700A0 (en) Medicaments and proteins
PL2066408T3 (en) Xanthoxyline-based composition and cosmetic use thereof
GB0615635D0 (en) Immunogenic proteins and uses thereof
EP2077262A4 (en) Iminopyridine derivative and use thereof
IL195493A0 (en) Combination preparations comprising bifeprunox and l-dopa
PL2012805T3 (en) Therapeutic composition and use
IL186337A0 (en) Stannsoporfin compositions and administration
IL191892A0 (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
ZA200900960B (en) Arylpiperazine derivatives and uses thereof
IL195532A0 (en) Combination preparations comprising slv308 and a l-dopa
EP1865777A4 (en) Stannsoporfin compositions and administration
EP2042153A4 (en) Skin cosmetic
ZA200810238B (en) Combination preparations comprising bifeprunox and L-DOPA
ZA200810239B (en) Combination preparations comprising SLV308 and a L-Dopa